We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2022 to Apr 2024
9:38 ET -- GSK PLC and Sanofi SA are among the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. A U.S. judge dismissed a series of lawsuits, numbering in the tens of thousands, around the Zantac heartburn treatment that both GSK and Sanofi had marketed. The judge in a multidistrict ruling concluded there was no scientific evidence to support the claim Zantac's active ingredient was carcinogenic. The decision could be appealed. U.S.-traded shares of GSK and Sanofi opened roughly 0.9% and 1.8% lower, respectively. Dow Jones & Co. owns Factiva. (robb.stewart@wsj.com)
(END) Dow Jones Newswires
December 07, 2022 09:53 ET (14:53 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
